Evidence map›Paper›PMID 38689518›Full record

Trial reportEpilepsia open2024

A multicenter randomized controlled feasibility trial of a digital self-management intervention for adults with epilepsy.

Rosa Michaelis, Susanne Knake, Felix Rosenow, Wenke Grönheit, Hajo Hamer, Bettina Schmitz, Alison Accarie, Peter Dedeken, Ilka Immisch, Lena Habermehl and 11 more

Abstract readRandomized Controlled TrialMulticenter Study
In one paragraph

Trial report in Epilepsia open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Rosa MichaelisRuhr-Epileptology, Department of Neurology, University Hospital Knappschaftskrankenhaus Bochum, Ruhr University Bochum, Bochum, Germany.ORCID https://orcid.org/0000-0002-2577-0824
Susanne KnakeDepartment of Neurology, Epilepsy Center Hessen, University Hospital and Philipps-University Marburg, Marburg, Germany.
Felix RosenowDepartment of Neurology, Epilepsy Center Frankfurt Rhine-Main, Center of Neurology and Neurosurgery, University Hospital and Goethe-University Frankfurt, Frankfurt, Germany.
Wenke GrönheitRuhr-Epileptology, Department of Neurology, University Hospital Knappschaftskrankenhaus Bochum, Ruhr University Bochum, Bochum, Germany.
Hajo HamerEpilepsy Center, Department of Neurology, University of Erlangen-Nürnberg, Erlangen, Germany.ORCID https://orcid.org/0000-0003-1709-8617
Bettina SchmitzStroke Unit, and Center for Epilepsy, Department of Neurology, Vivantes Humboldt-Klinikum Berlin, Berlin, Germany.
Alison AccarieNeuroventis BV, Overijse, Belgium.
Peter DedekenNeuroventis BV, Overijse, Belgium.
Ilka ImmischDepartment of Neurology, Epilepsy Center Hessen, University Hospital and Philipps-University Marburg, Marburg, Germany.
Lena HabermehlDepartment of Neurology, Epilepsy Center Hessen, University Hospital and Philipps-University Marburg, Marburg, Germany.
Johann Philipp ZöllnerDepartment of Neurology, Epilepsy Center Frankfurt Rhine-Main, Center of Neurology and Neurosurgery, University Hospital and Goethe-University Frankfurt, Frankfurt, Germany.ORCID https://orcid.org/0000-0002-7245-2562
Catrin MannDepartment of Neurology, Epilepsy Center Frankfurt Rhine-Main, Center of Neurology and Neurosurgery, University Hospital and Goethe-University Frankfurt, Frankfurt, Germany.ORCID https://orcid.org/0000-0001-6663-2631
Tim WehnerRuhr-Epileptology, Department of Neurology, University Hospital Knappschaftskrankenhaus Bochum, Ruhr University Bochum, Bochum, Germany.ORCID https://orcid.org/0000-0003-3319-2339
Jörg WellmerRuhr-Epileptology, Department of Neurology, University Hospital Knappschaftskrankenhaus Bochum, Ruhr University Bochum, Bochum, Germany.
Jeanne CunyEpilepsy Center, Department of Neurology, University of Erlangen-Nürnberg, Erlangen, Germany.
Stephanie GollwitzerEpilepsy Center, Department of Neurology, University of Erlangen-Nürnberg, Erlangen, Germany.ORCID https://orcid.org/0000-0002-6430-7947
Florian LoschStroke Unit, and Center for Epilepsy, Department of Neurology, Vivantes Humboldt-Klinikum Berlin, Berlin, Germany.
Kirsten KrämerStroke Unit, and Center for Epilepsy, Department of Neurology, Vivantes Humboldt-Klinikum Berlin, Berlin, Germany.
Kevin Steffen VossVoss Clinical Consulting GbR, Spaichingen, Germany.
Gerd HeinenRingpraxis Berlin, Berlin, Germany.
Adam StrzelczykDepartment of Neurology, Epilepsy Center Frankfurt Rhine-Main, Center of Neurology and Neurosurgery, University Hospital and Goethe-University Frankfurt, Frankfurt, Germany.ORCID https://orcid.org/0000-0001-6288-9915

Funding

Neuroventis
6 · The paper itself

Abstract

objectiveSelf-management interventions may enhance health-related quality of life (HRQoL) in epilepsy. However, several barriers often impair their implementation in the real world. Digital interventions may help to overcome some of these barriers. Considering this, the Helpilepsy Plus Prototype was developed as a prototype smartphone-delivered self-care treatment program for adults with epilepsy.

methodsThe 12-week Helpilepsy Plus Prototype was evaluated through a randomized controlled feasibility trial with a waiting-list control (WLC) group. Outcome measurement at baseline and at 12 weeks assessed adherence to the prototype intervention and changes in epilepsy-related outcomes. The primary endpoint was patient autonomy measured with EASE, and secondary endpoints included HRQoL measured with QOLIE-31, health literacy measured with HLQ, anxiety, and depression symptoms measured with HADS. Semi-structured interviews were conducted with a heterogeneous sample of participants to assess user-friendliness and usefulness. The prototype program was delivered through the Neuroventis Platform (Neuroventis, BV, Overijse, Belgium), a certified medical device (under EU/MDD Class I, and EU/MDR grace period).

resultsNinety-two patients were included (46 in the intervention group, 46 in WLC). Most participants (63%, 58/92 women, median age 30 years) had pharmacoresistant epilepsy (61%, 56/92). Only 22% of participants (10/46) in the intervention group completed at least half of all intervention sessions. No significant differences between the intervention group and WLC were observed. Although there was a larger proportion of patients in the intervention group with meaningful improvements in HRQoL compared to WLC (19/46 versus 11/46), the difference was not significant (p = 0.119). Qualitative feedback showed that participants would appreciate more personalization, such as adaptation of the content to their current epilepsy knowledge level, a more interactive interface, shorter text sections, and interaction through reminders and notifications. SIGNIFICANCE: Digital interventions should allow sufficient scope for personalization and interaction to increase patient engagement and enable benefits from self-care apps. Feedback loops allow the participatory development of tailored interventions. PLAIN LANGUAGE SUMMARY: In this study, we investigated the effectiveness of an app-based self-help intervention. Study participants were either randomly assigned to a group that had access to the app or a group that received access to the app after the end of the study. Although a larger proportion of participants in the intervention group showed a relevant improvement in quality of life, the difference between the two groups was not statistically significant. Less than one-fifth of participants in the intervention group attended at least half of all intervention sessions; patient feedback showed that patients required more personalization and interactive options.

Indexed as

EpilepsyFeasibility StudiesQuality of LifeSelf-ManagementAdultFemaleHumansMaleMiddle AgedMobile ApplicationsSmartphoneTreatment OutcomeYoung Adulthealth literacyHelpilepsymobile healthpatient autonomyquality of life

Identifiers

PMID38689518
PMCPMC11145620

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.